The ClearCyte platform is redesigned and re-engineered to meet more stringent processing and standardisation performance measures and deliver a yearly scanning capacity for each platform of over 40,000 samples.

The newly designed slide loader, microscope and stage components have also increased the reliability and functionality of the platform and improved software also allowed for a more interactive relationship with PMI Labs’ international partners to aid in the quality control and quality assurance programs, the company said.

The original intellectual property for ClearCyte was developed by the BC Cancer Agency and subsequently licensed to PMI Labs which develops the technology into a medical device and clinically available service.